CONMED Corporation's latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 5 Aug 2026Shows how the company performed in the first half of 2026, helping investors understand if the business is growing.
Lets investors know the company shared detailed financial information about its recent performance.
A new CFO manages company money, so his background in healthcare finance at Certara, Cue Health, and Becton Dickinson matters.
Company reduces debt by repurchasing bonds early, which can improve finances if it saves money on interest.
Extra available loans give the company flexibility to fund buybacks or operations without rushing to raise new money.
New board members from Johnson & Johnson and other firms bring healthcare expertise to guide the company.
Shows early-year performance across surgery product lines, helping track if growth is continuing.
Stocky reads CONMED Corporation's official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
CONMED Corporation's most recent tracked filing was a 10-Q on 29 Jul 2026: Reports second quarter 2026 financial results.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 5 Aug 2026.